miRNA-34a联合miRNA-4530在乳腺癌中的表达及其对新辅助化疗疗效的预测  

Expressions of miRNA-34a and miRNA-4530 in breast cancer and their value in predicting the efficacy of neoadjuvant chemotherapy

作　　者：张静[1] 石义鹭 王妍[3] 张洋[1] 欧瑞津 闫敏 王晓宇 孙平[1] ZHANG Jing;SHI Yilu;WANG Yan;ZHANG Yang;OU Ruijin;YAN Min;WANG Xiaoyu;SUN Ping(Teaching and Research Office of Anatomy,Mudanjiang Medical University,Heilongjiang,Mudanjiang 157000,China;Hongqi Hospital Affiliated to Mudanjiang Medical University,Heilongjiang,Mudanjiang 157000,China;Teaching and Research Office of Pathogenesis,Mudanjiang Medical University,Heilongjiang,Mudanjiang 157000,China;School of Basic Medicine,Mudanjiang Medical University,Heilongjiang,Mudanjiang 157000,China)

机构地区：[1]牡丹江医学院解剖教研室,黑龙江牡丹江157000 [2]牡丹江医学院附属红旗医院,黑龙江牡丹江157000 [3]牡丹江医学院病原教研室,黑龙江牡丹江157000 [4]牡丹江医学院基础医学院,黑龙江牡丹江157000

出　　处：《中国医药科学》2023年第11期38-41,共4页China Medicine And Pharmacy

基　　金：黑龙江省省属高等学校基本科研业务费科研项目(2020-KYYWF-0784);牡丹江医学院科研启动基金(2021-MYBSKY-026,2021-MYBSKY-028);黑龙江省医药卫生科研项目(20220101020737)。

摘　　要：目的探讨乳腺癌中的miRNA-34a联合miRNA-4530表达及其预测新辅助化疗疗效的价值。方法选取2020年1—12月经牡丹江医学院附属红旗医院就诊的70例进行新辅助化疗的原发性乳腺癌患者,依据新辅助化疗疗效将完全缓解(CR)和部分缓解(PR)划分为敏感组,疾病进展(PD)和稳定(SD)划分为耐药组,每组各35例。统计分析不同病理分期、分子分型患者的循环血miRNA-34a、miRNA-4530的检测结果,并统计分析两组循环血miRNA-34a、miRNA-4530水平,分析循环血miRNA-34a、miRNA-4530水平对乳腺癌新辅助化疗疗效的预测效能。结果病理分期Ⅱ期患者的循环血miRNA-34a、miRNA-4530表达水平均高于Ⅲ期患者,差异有统计学意义(P<0.05),分子分型Luminal A型、Luminal B型、人表皮生长因子受体(HER)-2过表达型、三阴型患者的循环血miRNA-34a、miRNA-4530表达水平均逐渐降低,差异有统计学意义(P<0.05)。敏感组患者的循环血miRNA-34a、miRNA-4530表达水平均高于耐药组,差异有统计学意义(P<0.05)。循环血miRNA-34a、miRNA-4530表达水平联合检测预测乳腺癌新辅助化疗疗效的灵敏度、特异度高于单独检测,差异有统计学意义(P<0.05)。结论乳腺癌中的miRNA-34a联合miRNA-4530表达预测新辅助化疗疗效的价值高。Objective To investigate the expressions of microRNA(miRNA)-34a and miRNA-4530 in breast cancer and their value in predicting the efficacy of neoadjuvant chemotherapy.Methods A total of 70 patients with primary breast cancer who underwent neoadjuvant chemotherapy at Hongqi Hospital Affiliated to Mudanjiang Medical University from January to December 2020 were selected as the study subjects.Based on the efficacy of neoadjuvant chemotherapy,patients with complete remission(CR)and partial remission(PR)were divided into a sensitive group(n=35),and patients with disease progression(PD)and stable disease(SD)were divided into a drug-resistant group(n=35).The results of circulating blood miRNA-34a and miRNA-4530 in patients with different pathological stages and molecular typing were statistically analyzed,and the predictive efficiency of circulating blood miRNA-34a and miRNA-4530 levels on the efficacy of neoadjuvant chemotherapy for breast cancer in both groups was analyzed.Results The expression levels of circulating blood miRNA-34a and miRNA-4530 were higher in StageⅡpatients than in StageⅢpatients in pathological staging,with statistically significant differences(P<0.05).The expression levels of circulating blood miRNA-34a and miRNA-4530 gradually decreased with increasing molecular typing from Luminal A,Luminal B,human epidermal growth factor receptor(HER)-2 overexpressing to triple negative,with statistically significant differences(P<0.05).The expression levels of circulating blood miRNA-34a and miRNA-4530 were higher in the sensitive group than in the drug-resistant group,with statistically significant differences(P<0.05).The sensitivity and specificity of circulating blood miRNA-34a and miRNA-4530 expression levels by combined test in predicting the efficacy of neoadjuvant chemotherapy for breast cancer were higher than those by single test,with statistically significant differences(P<0.05).Conclusion The combined test of miRNA-34a and miRNA-4530 expressions is of high value in predicting the efficacy of ne

关 键 词：乳腺癌 新辅助化疗 疗效 miRNA-34a miRNA-4530 表达 预测 

分 类 号：R737.9[医药卫生—肿瘤]